Navigation Links
Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis

ies Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra(r) and Neurontin(r), the effects of competition on our innovative products, especially Copaxone(r) sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not cove
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, ... the second Phase III clinical study for Ozenoxacin, ... impetigo.  Medimetriks owns the exclusive U.S. rights to ... trial, conducted at 44 centers with an emphasis ... patients aged 2 months and older with a ...
(Date:7/30/2015)... Global ENT (Ear, Nose, ... USD 23.01 million in 2022, according to a new ... geriatric population, increasing prevalence of ear, nose, and throat ... among target customer base are expected serve this market ... According to estimates published by the WHO, 15% of ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5
... Findings Reinforce March of Dimes Message: Start Taking a ... 11 Women who take folic acid supplements for ... cut their risk of having a premature baby by ... online journal, PLOS Medicine.The study links pre-conceptional folate supplementation ...
... Announces Positive Top Line Results of its Clinical Study ... Mass., May 11 Logical Therapeutics, Inc (Logical), a ... treat diseases associated with inflammation, today announced that Peter ... has been elected to the Company,s Board of Directors. ...
Cached Medicine Technology:Taking Folic Acid for a Year Before Pregnancy May Reduce Risk of Preterm Birth 2Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 2Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 3Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 4
(Date:7/30/2015)... ... 2015 , ... The New Jersey Innovation Institute (NJII), acting ... Health, has received a $2.9 million grant from the Office of the National ... and Human Services (HHS). NJII will help the Department of Health ensure the ...
(Date:7/30/2015)... ... July 30, 2015 , ... InventHelp, a leading inventor service ... personal-care device that makes it easy to apply lotion or medication to a hard-to-reach ... assistance when applying lotion or medication to the back, and provides thorough coverage. The ...
(Date:7/30/2015)... ORLEANS (PRWEB) , ... July 30, 2015 , ... Author ... and take charge of their health in his new self-help book, “ Consciously Healing ... Llanos’ new book promotes a simple message: “If we take responsibility for ourselves, we ...
(Date:7/30/2015)... ... , ... Summer is the dry eye season, especially in parts of the ... and hot 2015 summer season and the dry eye rate in the hot spots ... the 2015 summer season and identify the primary dry eye hot spots on her ...
(Date:7/30/2015)... ... July 30, 2015 , ... HEALTHCAREfirst , the leading ... announced today that it is hosting a free webinar detailing the 2016 proposed rule ... HEALTHCAREfirst Consultant and former Vice President of Regulatory Affairs for the National Association for ...
Breaking Medicine News(10 mins):Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 3Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 3Health News:HEALTHCAREfirst Announces Home Health Industry Regulatory Review Webinar 2
... , NEW YORK, Dec. 10 SIRIUS ... Doctor Radio Reports: Kids and Video Games - What ... by journalist Perri Peltz on which she and a panel of experts ... effects they have on children. , (Logo: http://www.newscom.com/cgi-bin/prnh/20080819/NYTU044LOGO ) , ...
... , SALEM, Ore., Dec. 10 West Coast Bank,s ... Bears for children hospitalized at the Salem Hospital Pediatric Wing and ... Bears at the branch, 5686 Commercial St. SE, Suite 110 on ... BSN CPN, Nurse Manager of Pediatrics at Salem Hospital said, "The ...
... of alcoholic beverages (at least three to four drinks per ... a 30 percent increased risk of breast cancer recurrence, according ... may be most susceptible to the effects of alcohol on ... of this study will be presented December 9-13 at the ...
... to die or be disabled by midlife, study finds, , THURSDAY, ... a man,s risk of dying or becoming disabled by the time ... findings are from a study that began following 411 South London ... those who at age 10 displayed antisocial behavior (such as skipping ...
... ... leader in Sales and Operations Planning (S&OP) solutions, announced a program ... JDA The Steelwedge "i2 Exchange Program" address i2 customers that ... recently announced merger between i2 and JDA (formerly Manugistics), or are ...
... , RANCHO CORDOVA, Calif., Dec. 10 ThermoGenesis Corp. (Nasdaq: ... processing and storing adult stem cells, said today that Craig ... industry experience, has been named to the Company,s board of ... to six. , Moore is currently associated with several public ...
Cached Medicine News:Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: Kids and Video Games - What You Should Know Before You Buy' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: Kids and Video Games - What You Should Know Before You Buy' 3Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: Kids and Video Games - What You Should Know Before You Buy' 4Health News:Alcohol consumption may increase breast cancer recurrence risk 2Health News:Bad Behavior as a Kid Linked to Early Death in Men 2Health News:Leading Sales and Operations Planning (S&OP) Provider Steelwedge Announces i2 Exchange Program 2Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 2Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 3Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 4
Inquire...
Sebia's Hb AFSC Control provides excellent resolution of normal hemoglobins A & F and abnormal hemoglobins S & C. The control is designed for use with Sebia's Hydragel Hemoglobin and Hydragel Acid He...
... and Hypergamma Controls are designed ... agarose gels or Sebia's ... unique control manufacturing process preserves ... other serum components, presenting a ...
The HYRYS™ 2 densitometer is reflective of Sebia's expertise in the development and design of imaging systems and densitometers utilized in the electrophoresis field....
Medicine Products: